

Eurofins strengthens its Asia Pacific footprint with the acquisition of the NM Group of Laboratories in Malaysia

30 November 2015

Eurofins Scientific (EUFI.PA), the global leader in food and environment testing services, announces that it has acquired the NM Group of Laboratories (NML), one of the leading private laboratories in Malaysia for food and environment testing.

NML employs about 120 staff across its 3 facilities, strategically located in the northern and southern parts of the country. Established in 1980 originally for testing of dried rubber, NML has developed into one of the leading private laboratories providing comprehensive analytical services for food and environment testing, as well as for rubber testing.

Malaysia has a well-developed market for environment testing, especially in water and soil contamination given its status as one of the top exporters of liquefied natural gas (LNG)¹. Furthermore, with the third highest GDP per capita² in the ASEAN³ region, sustained consumption growth also supports positive outlook for testing in food and other consumer products. The acquisition therefore provides Eurofins entry into this attractive testing market, a strong platform to roll-out a broader service offering, and reinforces the Group's growing footprint in the region. In return, NML will gain access to the complete infrastructure and capability of the Group, which should allow substantial expansion of the range of services it offers to both domestic and international customers, thereby accelerating its market share expansion.

Comment from **Dr. Gilles Martin**, Eurofins CEO: "NML provides Eurofins a good entry into the analytical testing market in Malaysia and reinforces our footprint in this rapidly-growing region. We are looking forward to contributing to strengthening NML's position in its market, as well as expanding the portfolio of tests it makes available to the Malaysian government and industries by offering the full range of services and capabilities of the Eurofins Group through NML."

For more information, please visit www.eurofins.com or contact:

Eurofins Investor Relations Phone: +32-2-766 1620 E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food, environment and pharmaceutical products testing. It is also one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.

With 20,000 staff in around 200 laboratories across 38 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

¹ http://www.statista.com/statistics/274528/major-exporting-countries-of-lng/

² https://en.wikipedia.org/wiki/List_of_ASEAN_countries_by_GDP_(nominal)

³ Association of South East Asian Nations

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.